Durable response to the combination of pembrolizumab and nab-paclitaxel in a metastatic extrahepatic cholangiocarcinoma: A case report and literature review

Sirui Tan\textsuperscript{1}, Jing Yu\textsuperscript{1}, Qiyue Huang\textsuperscript{1}, Nan Zhou\textsuperscript{1}, Xianze Xiong\textsuperscript{2*} and Hongfeng Gou\textsuperscript{1*}

\textsuperscript{1}Department of Medical Oncology, Gastric Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China, \textsuperscript{2}Department of Bile Duct Surgery, West China Hospital, Sichuan University, Chengdu, China

\textbf{Background:} Cholangiocarcinoma (CCA) is a highly aggressive malignant tumor with poor overall survival. Although the first-line standard chemotherapy (gemcitabine plus cisplatin) combined with immunotherapy has yielded positive results with survival prolongation, the efficacy remains unsatisfactory, and new treatment modalities need to be explored.

\textbf{Case presentation:} We report the case of a patient with metastatic extrahepatic CCA who achieved a durable response and good tolerance to the combination treatment of pembrolizumab and nab-paclitaxel following progression on gemcitabine plus capecitabine chemotherapy. The tumor samples of the patient revealed low TMB, MSS, negative PD-L1 expression, and negative CD8\textsuperscript{+} TIL expression. This patient was treated with 3 cycles of pembrolizumab plus nab-paclitaxel and cisplatin, followed by 5 cycles of pembrolizumab plus nab-paclitaxel. Finally, 10 cycles of pembrolizumab monotherapy were administered. The patient survived for over 27 months after the initiation of combined therapy and was still in continuous remission at the last follow-up.

\textbf{Conclusion:} As far as we know, this is the first report that pembrolizumab plus nab-paclitaxel successfully treated a patient with advanced CCA. This combination therapy might be a potential treatment option for patients with cholangiocarcinoma, and further clinical trials are needed to explore the outcomes.

\textbf{KEYWORDS} cholangiocarcinoma, immunotherapy, nab-paclitaxel, pembrolizumab, tumor microenvironment
Background

Cholangiocarcinoma (CCA) originates from the bile duct cells and accounts for 3% of digestive system tumors (Rizvi and Gores, 2013). Its morbidity and mortality have risen in recent years (Khan et al., 2019). According to anatomical location, Cholangiocarcinoma is categorized as intrahepatic cholangiocarcinoma (iCCA) and extrahepatic cholangiocarcinoma (eCCA). In addition, eCCA can be divided into perihilar CCA (pCCA) and distal CCA (dCCA) (Rizvi and Gores, 2013). Cholangiocarcinoma is highly aggressive, and surgery is still the primary treatment option. However, more than two-thirds of patients are unsuitable for surgery at the initial diagnosis (Jarnagin et al., 2001). Patients who have undergone radical surgery have a high rate of recurrence and metastasis (Jung et al., 2012). The prognosis of metastatic cholangiocarcinoma is extremely poor, with a 5-year overall survival (OS) rate of about 10% (Everhart and Ruhl, 2009; Tyson and El-Serag, 2011).

For patients with advanced cholangiocarcinoma, systemic chemotherapy is the backbone of palliative care, and commonly used agents include gemcitabine, platinum, and fluoropyrimidines. The United Kingdom ABC-02 study established cisplatin and gemcitabine (CisGem) as the reference first-line regimen, with an improved OS (11.7 vs. 8.1 months) compared with gemcitabine monotherapy (Valle et al., 2010). Recently, in a promising single-arm phase II study, the combination of CisGem plus nab-paclitaxel provided a response rate (RR) of 45% and a median OS of 19.2 months in chemotherapy-naïve patients (Shroff et al., 2019). The median OS with first-line reference doublet is less than one year, and the high incidence of adverse effects of intensified triple-agent cannot be ignored. In the second-line setting, the only phase III trial is the ABC-06 study which assessed the benefit of the regimen of mFOLFOX (oxaliplatin, leucovorin, 5-fluorouracil) compared with active symptomatic control in CisGem-refractory patients. Although the median OS of patients receiving mFOLFOX was statistically significant, the OS improvement was modest (6.2 vs. 5.3 months) (Lamarca et al., 2021). The limited survival benefit of current chemotherapy options highlights the need to develop more effective therapeutic options. The molecular heterogeneities in CCA have been identified with the emergence of next-generation sequencing. The patients carrying fibroblast growth factor...
receptor 2 (FGFR2) fusion/rearrangement, isocitrate dehydrogenase (IDH) mutation, and neurotrophin receptor tyrosine kinase (NTRK) genes fusion may benefit from the corresponding targeted therapy (Mazzaferro et al., 2019; Abou-Alfa et al., 2020; Bekaii-Saab et al., 2020; Doebele et al., 2020; Lamarca et al., 2020; Rizzo et al., 2021b). However, these actionable molecular alterations usually occur in intrahepatic cholangiocarcinoma (Abou-Alfa et al., 2020; Montal et al., 2020; Rizzo et al., 2020).

In recent years, immune checkpoint inhibitors (ICIs) have shown outstanding efficacy in pan-tumors such as malignant melanoma, lung cancer, urothelial cancer, and liver cancer (Balar et al., 2017; Eggermont et al., 2018; Xu et al., 2018; Mok et al., 2019). The results of early clinical trials of ICIs monotherapy (pembrolizumab, nivolumab, and durvalumab) in unselected patients with biliary tract cancer (BTC) provided limited activity, with response rate (RR) ranging between 3% and 13% (Rang et al., 2019; Ueno et al., 2019; Kim et al., 2020; Rizzo et al., 2021a). A number of different ICIs combinations are under investigation, and the combination of ICIs and chemotherapy (chemoimmunotherapy) has shown promising anti-tumor efficacy. Notably, data from the placebo-controlled, phase III TOPAZ-1 trial demonstrated that durvalumab plus CisGem significantly improved survival outcomes (12.8 vs. 11.5 months) compared to CisGem alone as a first-line treatment in advanced BTC (Oh et al., 2022). Patients receiving the chemoimmunotherapy also had an improved progression-free survival (7.2 vs. 5.7 months) and RR (26.7% vs. 18.7%). This combination is currently considered a new standard of care in first-line advanced BTC. The first-line, placebo-controlled phase 3 study of pembrolizumab (NCT04003636) in combination with CisGem is underway. Most chemoimmunotherapy trials in advanced BTC applied CisGem or oxaliplatin-based regimens as the chemotherapy backbone. However, the net benefit was not satisfying, and new combinations still need to be investigated. Here, for the first time, we report a patient with metastatic extrahepatic cholangiocarcinoma who had a durable response and good tolerance to pembrolizumab combined with nanoparticle albumin-bound (nab)-paclitaxel in a background of low tumor mutation burden (TMB), microsatellite stable (MSS), negative PD-L1 expression and negative CD8+ tumor-infiltrating lymphocyte (TIL) expression in the tumor microenvironment (TME).

Case presentation

On 15 April 2019, a 66-year-old man was admitted to the West China Hospital with pain in his lower back and jaundice of the skin and sclera. The patient has no other medical, family, or psychosocial history.

Computed tomography (CT) scan showed dilatation of the common bile duct, with thickened lower duct wall and mild enhancement. A radical pancreaticoduodenectomy was performed on 22 April 2019. Postoperative pathology revealed a moderately-poorly differentiated adenocarcinoma, with invasion to the common bile duct.
wall, duodenal wall and pancreatic parenchyma. Nerve invasion and intravascular emboli were also observed. There were no regional lymph node metastases. Immunohistochemical (IHC) analysis showed CK7(+), CK19(+), MUC-1 (+), MUC-2 (-), DPC-4 (+/-), CK (focal+), CDX-2 (-). The patient was diagnosed as stage IIIB-T4N0M0. Chest and abdominal CT were performed two months after surgery, showing no signs of tumor recurrence or metastasis. A total of 8 cycles of gemcitabine plus capecitabine (GEMCAP) as adjuvant chemotherapy was performed from 22 June 2019, to 18 December 2019. On 27 March 2020, abdominal CT showed multiple liver metastases with a 22 mm × 27 mm mass forming lesion in segment 6 (S6) and a 9 mm × 13.5 mm mass forming lesion in S8 (Figure 1A). Meanwhile, laboratory examinations showed that the patient’s carcinoembryonic antigen (CEA) was 7.69 ng/ml (normal level < 3.4 ng/ml), and the carbohydrate antigen 19–9 (CA 19–9) was 33.10 U/ml (normal level < 22 U/ml). Subsequently, the patient underwent next-generation sequencing (NGS) on surgically resected specimens, and the results showed KRAS and TP53 mutations, TMB of 1 mutation/megabase, and MSS. Multiple immunofluorescence was used to detect TME (Figure 2), indicating that PD-L1 expression was negative (TPS < 1%, CPS < 1) and CD8+ TIL expression was quantified at 0.21% of the tumor parenchyma and 1.15% of the stroma (Table 1). Based on the results of Gainor et al. (2016), the patient was judged “negative” for CD8+TIL expression. Four months after adjuvant chemotherapy, the patient developed metastasis, and the GEMCAP regimen was

| Cellular components              | Tumor parenchyma | Tumor stroma |
|----------------------------------|------------------|--------------|
|                                   | Number/mm² %     | Number/mm² % |
| T cell related indicators        |                  |              |
| CD3                              | 227 3.69         | 790 14.03    |
| CD4                              | 15 0.25          | 77 1.37      |
| CD8                              | 17 0.21          | 65 1.15      |
| FoxP3                            | 15 0.24          | 49 0.88      |
| PD-1+CD8⁺                       | 0 0.00           | 0 0.00       |
| CD4⁺FoxP3⁺                       | 1 0.02           | 6 0.10       |
| Macrophage related indicators    |                  |              |
| CD68⁻CD163⁺                     | 0 0.00           | 1 0.02       |
| CD68⁺CD163⁺                     | 36 0.44          | 166 2.94     |
| PD-L1⁻CD68⁺                     | 1 0.01           | 4 0.06       |
| NK cell related indicators       |                  |              |
| CD56bright                      | 7 0.11           | 43 0.77      |
| CD56dim                         | 72 1.17          | 128 2.27     |
| B cell related indicators        |                  |              |
| CD20                             | 14 0.22          | 82 1.45      |

**FIGURE 3**
PET-CT in August 2020 showed disappeared hypermetabolic activities in the hepatic lesions and no clear sign of tumor recurrence and metastasis throughout the body. S6, Segment 6; S8, Segment 8.
The response of tumor marker to chemoimmunotherapy. CA19–9, carbohydrate antigen 19–9.

FIGURE 4

Tumor marker trend

and was still in continuous remission at the last follow-up in July 2022 (Figure 1A).

Discussion

Here, we report on the efficacy and tolerability of a combination of pembrolizumab plus nab-paclitaxel as a second-line therapy after GEMCAP regimen progression in a patient with low TMB, MSS, negative PD-L1 expression, and negative CD8⁺ TIL expression extrahepatic cholangiocarcinoma.

Recent evidence suggests that cytotoxic agents work synergistically with immunotherapy by boosting anti-tumor immunity. Cytotoxic agents majoring modulate the TME by inducing immunogenic tumor cell death and inhibiting mechanisms utilized by tumor cells for immune evasion (Galluzzi et al., 2015). The TOPAZ-1 phase III trial has shown a benefit for chemoimmunotherapy (durvalumab plus CisGem) compared to chemotherapy alone. Although the survival benefits are limited, the survival curves indicated that 24.9% of patients are still alive after two years and showed unprecedented durable responses that chemotherapy alone couldn’t reach (Oh et al., 2022). Based on this encouraging data, many trials comparing the effects of ICI alone or in combination with chemotherapy, such as KEYNOTE-966 (pembrolizumab + CisGem), IMBRACE 151 (atezolizumab + CisGem), M7824 (bintrafuspare + CisGem), are ongoing. Most trials applied chemoimmunotherapy as the first-line treatment, with CisGem regimen chemotherapy backbone. In this case, the patient was treated with nab-paclitaxel-based chemoimmunotherapy as second-line therapy and achieved a long-lasting response. It is worth mentioning that our patient started with doublet chemotherapy in the second line of treatment but experienced unacceptable adverse effects and declining performance status. Therefore, single-agent chemotherapy combined with immunotherapy might be a good strategy from the perspective of patient tolerance in the second-line setting. The anti-tumor activity of nab-paclitaxel plus immunotherapy has been validated, with acceptable toxicity in backbone treatment in other tumors (Schmid et al., 2018; Giannatempo et al., 2020; Wang et al., 2022). Nab-paclitaxel has been widely explored in patients with BTC in previous clinical trials (Sahai et al., 2018; Shroff et al., 2019; Woodford et al., 2021 June 28), while the efficacy of the combination of nab-paclitaxel plus immunotherapy as the second-line treatment in BTC patients has not been studied. Notably, nab-paclitaxel has a synergistic effect in combination with ICIs due to its special nanoparticle carrier (Martin et al., 2020). The underlying mechanisms are associated with enhancing antigen-presenting cells (APCs) antigen presentation ability, affecting the tumor immune microenvironment, and

considered the first-line treatment. Due to the limited benefit of the standard second-line chemotherapy (FOLFOX), a switch to second-line systemic therapy with nab-paclitaxel and cisplatin (AP) plus pembrolizumab was recommended by our tumor conference. Before treatment, written informed consent was obtained from the patient who presented Eastern Cooperative Oncology Group performance score (ECOG) of zero. In April 2020, the treatment with pembrolizumab plus AP was initiated. The first radiological imaging in June 2020 showed a stable disease after two cycles (Figure 1A). Due to grade 3 vomiting and grade 2 nausea (CTCAE5.0), cisplatin was discontinued after three cycles. Five cycles of pembrolizumab plus nab-paclitaxel were performed from July to October 2020. Although the positron emission tomography-computed tomography (PET-CT) in August 2020 showed no hypermetabolic activities in the hepatic lesions and no clear toxicities (grade 2 leukopenia, grade 2 neutropenia and grade 1 anemia) during chemoimmunotherapy.

Subsequent ten cycles of pembrolizumab monotherapy (the maintenance therapy) were administered and stopped in May 2021, when grade 2 checkpoint inhibitor pneumonitis (CIP) was observed (Figure 1B). The prednisolone (initial dose at 1 mg/kg/day–2 mg/kg/day) was administered, and the dose was reduced by 5 mg per week. The final therapy was glucocorticosteroid treatment, which started in May 2021 and lasted for six weeks, and the patient did not receive any anti-tumor treatment since then. The patient survived for over 27 months after the chemoimmunotherapy.
promoting T lymphocyte activation to kill tumor cells (Martin et al., 2020).

Selecting people who can benefit from immunotherapy remains one of the biggest problems. MSI-H/dMMR, high TMB, PD-L1 positive expression, and high immune cell infiltration are currently considered predictive biomarkers of response to immunotherapy or its combination with chemotherapy (Zhao et al., 2019). Previous studies have demonstrated great clinical activity of ICIs in BTC patients with microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR) (Le et al., 2017). However, the incidence of dMMR/MSI-H BTC is less than 5% (Winkelmann et al., 2018; Goepfert et al., 2019). High TMB has been only reported in 5.9% of BTC patients, and the median TMB of BTC is about two mutations/megabase (Nakamura et al., 2015; Lin et al., 2021). A phase II study (JS001-ZS-BC001) of toripalimab (PD-1 inhibitor) plus S-1 and gemcitabine had promising survival benefits in untreated BTC patients with ORR of 27.1% and a median OS of 16 months (Li et al., 2021). Biomarker analysis revealed that TMB was not associated with treatment response or survival outcomes in JS001-ZS-BC001, which was further validated by the phase II study of camrelizumab (PD-1 inhibitor) plus gemcitabine and oxaliplatin in untreated BTC patients (Chen et al., 2020). The efficacy of pembrolizumab on PD-L1-positive and negative CCA was analyzed in the KEYNOTE-158 trial. PD-L1 positivity was not associated with superior survival outcomes, and there were no significant differences in median PFS (1.9 vs. 2.1 months) or OS (7.2 vs. 9.3 months) between PD-L1-positive and negative subgroups (Bang et al., 2019). In the subgroup of TOPAZ-1 trial, the addition of durvalumab to chemotherapy benefited patients with tumors characterized by a PD-L1 tumor area positivity (TAP) of 1% or greater and a TAP of less than 1%, suggesting that PD-L1 status may have limited value in predicting clinical benefit with chemoimmunotherapy in BTC (Oh et al., 2022). Additionally, trials of chemoimmunotherapy have been completed for patients with non-small cell lung cancer (NSCLC), even independent of PD-L1 status. In the KEYNOTE-189 and KEYNOTE-407 trials, NSCLC patients with less than 1% PD-L1 expression also responded to chemoimmunotherapy, and PD-L1 expression did not correlate with the clinical benefit (Gandhi et al., 2018; Yan et al., 2018). It is worth mentioning that the accuracy of these biomarkers is controversial. The biological process of antitumor immune response is complicated, involving cancer cells and cells in the TME. The different biomarkers accounted for few aspects of the overall process and, therefore, cannot be used to predict efficiently. For example, in this case, we comprehensively analyzed the genomic alterations and the immune microenvironment and found that our patient, with MSS, low TMB, negative CD8+ TIL and PD-L1 expression, can still benefit from chemoimmunotherapy, even in the second-line treatment. Further exploration of predictive biomarkers of response to immunotherapy for BTC is needed.

The optimal duration of ICI maintenance therapy remains controversial. Currently, the immunotherapy duration designed in most studies for advanced tumors is two years or discontinued when tumor progression or intolerable toxicities appear. However, several studies have shown that patients who were sensitive to immunotherapy but discontinued it due to immune-related adverse events had similar survival outcomes to those who completed the established therapy, indicating that early discontinuation of immunotherapy had no impact on survival (Schadendorf et al., 2017; Horiguchi et al., 2018; Kimura et al., 2019). In the current case, no significant change in tumor size was observed after switching to pembrolizumab monotherapy, but immune-related adverse effects occurred. Interestingly, no considerable tumor changes were observed even 14 months after discontinuing maintenance therapy. Although controllable CIP occurred on this patient, we will consider reintroducing nab-paclitaxel plus pembrolizumab if tumor progression in the following follow-ups because the patient has been off this treatment for more than one year.

**Conclusion**

ICI combined with nab-paclitaxel might be a potential treatment option for patients with CCA and further clinical trials are needed to explore the outcomes.

**Data availability statement**

The original contributions presented in the study are included in the article, further inquiries can be directed to the corresponding author.

**Ethics statement**

The study involving human participant was reviewed and approved by the ethics committee on biomedical research, West China Hospital of Sichuan University. The patient provided written informed consent for the publication of any potentially identifiable images or data included in this article.

**Author contributions**

All authors participated in the diagnosis and treatment process. ST and JY collected the data and wrote the manuscript. JY, QH, and NZ helped collect literature and participated in the follow-up course.
HG developed the treatment plan and examined the language. All authors approved the submitted version.

Funding

This work was supported by the Health Commission of Sichuan Province Program (21PJ007).

Acknowledgments

We thank the patient and his family for allowing us to publish his clinical case.

References

Abou-Alfa, G. K., Macarulla, T., Javle, M. M., Kelley, R. K., Lubner, S. J., Adeva, J., et al. (2020). Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClariDHY): A multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet. Oncol. 21 (6), 796–807. doi:10.1016/S1470-2045(20)30157-1

Balar, A. V., Castellano, D., O'Donnell, P. H., Grivas, P., Vuky, J., Powles, T., et al. (2017). First-line pembrolizumab in cisplatin-inefficient patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): A multicentre, single-arm, phase 2 study. Lancet. Oncol. 18 (11), 1483–1492. doi:10.1016/S1470-2045(17)30616-2

Bang, Y. J., Chuang, H. C., Naigal, A., Kelley, R. K., Kelley, R. K., et al. (2019). Pembrolizumab (pembrolizumab) for advanced biliary adenocarcinoma: Results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies. J. Clin. Oncol. 37, 4079. doi:10.1200/jco.2019.37.15_suppl.4079

Bekai-Saah, T. S., Valle, J. W., Van Cutsem, E., Rimassa, L., Furuse, J., Ioka, T., et al. (2020). FIGHT-302: First-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements. Future Oncol. 16 (30), 2385–2399. doi:10.2217/fon-2020-0429

Chen, X., Xu, W., Wu, H., Gu, Y., Shao, Y., Shao, Q., et al. (2020). Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: A single-arm, open-label, phase II trial. J. Immunother. Cancer 8 (2), e001240. doi:10.1136/jitc-2020-001240

Doebele, R. C., Drilon, A., Paz-Ares, L., Siena, S., Shaw, A. T., Farago, A. F., et al. (2020). Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: Integrated analysis of three phase 1-2 trials. Lancet. Oncol. 21 (2), 271–282. doi:10.1016/S1470-2045(19)30691-6

Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., et al. (2018). Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N. Engl. J. Med. 378 (19), 1789–1801. doi:10.1056/NEJMoa1802357

Everhart, J. E., and Ruhl, C. E. (2009). Burden of digestive diseases in the United States Part III. Liver, biliary tract, and pancreas. Gastroenterology 136 (4), 1314–1414. doi:10.1053/j.gastro.2009.02.038

Gainor, J. F., Shaw, A. T., Sequist, L. V., Fu, X., Azzoli, C. G., Piotrowska, Z., et al. (2016). EGFR mutations and alk rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: A retrospective analysis. Clin. Cancer Res. 22 (18), 4585–4593. doi:10.1158/1078-0432.CCR-15-3101

Galluzzo, L., Buceri, A., Kepp, O., Zitovgel, L., and Kroemer, G. (2015). Immunological effects of conventional immunotherapy and targeted anticancer agents. Cancer Cell 28 (6), 690–714. doi:10.1016/j.ccell.2015.10.012

Gandhi, L., Rodriguez-Arbus, D., Gadgel, S., Esteban, E., Felip, E., De Angelis, F., et al. (2018). Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378 (22), 2078–2082. doi:10.1056/NEJMoa1801005

Giannattasio, P., Raggi, D., Maranzino, L., Bandini, M., Fare, E., Calareso, G., et al. (2020). Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma: Interim results of the open-label, single-arm, phase II PEANUT study. Ann. Oncol. 31 (12), 1764–1772. doi:10.1016/s0923-7534(20)31912-4

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Mazzaferrro, V., El-Rayes, B. F., Drou Dsit Buset, M., Coto游击, C., Harris, W. P., Damjanov, N., et al. (2019). Dacetanzumab (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. Br. J. Cancer 120 (2), 165–171. doi:10.1038/s41416-018-0133-4

Mok, T. S. K., Wu, Y. L., Kudaka, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., et al. (2019). Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042). A randomised, open-label, controlled, phase 3 trial. Lancet 393 (10183), 1819–1830. doi:10.1016/S0140-6736(18)32409-7

Montal, R., Sia, D., Montironi, C., Leow, W. Q., Esteban-Fabro, R., Pinyol, R., et al. (2020). Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. J. Hepatol. 73 (2), 315–327. doi:10.1016/j.jhep.2020.03.008

Nakamura, H., Arai, Y., Totoki, Y., Shirota, T., Elzawahry, A., Kato, M., et al. (2015). Genomic spectra of biliary tract cancer. Nat. Genet. 47 (9), 1003–1010. doi:10.1038/ng.3735

Oh, D.-Y., He, A. R., Qin, S., Chen, L.-T., Okusaka, T., Vogel, A., et al. (2022). A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCiX) in patients (pts) with advanced biliary tract cancer (BTC). TOPAZ-1. J. Clin. Oncol. 40 (4), 378. doi:10.1200/JCO.2020.40.4_suppl.378

Rizvi, S., and Gores, G. J. (2013). Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 145 (6), 1215–1229. doi:10.1053/j.gastro.2013.10.013

Rizzo, A., Rizzi, A. D., and Brandi, G. (2021a). Durvalumab: An investigational anti-PD-L1 antibody for the treatment of biliary tract cancer. Expert Opin. Investig. Drugs 30 (4), 343–350. doi:10.1080/13543784.2021.1897102

Rizzo, A., Rizzi, A. D., and Brandi, G. (2021b). Pembrolizumab: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma. Cancer Treat. Res. Commun. 27, 100337. doi:10.1016/j.ctarc.2021.100337

Rizzo, A., Rizzi, A. D., Tober, N., Negro, M. C., Mosca, M., Palloni, A., et al. (2020). Second-line treatment in advanced biliary tract cancer. Today and tomorrow. Anticancer Res. 40 (6), 3013–3030. doi:10.21873/anticancerres.14282

Sahai, V., Catalano, P. J., Zalupska, M. M., Lubner, S. J., Menge, M. R., Nimeiri, H. S., et al. (2018). Nab-paclitaxel and gemcitabine as first-line treatment of advanced or metastatic cholangiocarcinoma: A phase 2 clinical trial. JAMA Oncol. 4 (12), 1707–1712. doi:10.1001/jamaoncol.2018.3277

Schadendorf, D., Wolchok, J. D., Hodi, F. S., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., et al. (2017). Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: A pooled analysis of randomized phase II and III trials. J. Clin. Oncol. 35 (34), 3807–3814. doi:10.1200/JCO.2017.73.2289

Schmid, P., Adams, S., Rugo, H. S., Schneweiss, A., Barrios, C. H., Iwata, H., et al. (2018). Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 379 (22), 2108–2121. doi:10.1056/NEJMoa1809615

Shroff, R. T., Javle, M. M., Xiao, L., Kaseb, A. O., Varadhachary, G. R., Wolff, R. A., et al. (2019). Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: A phase 2 clinical trial. JAMA Oncol. 5 (6), 824–830. doi:10.1001/jamaoncol.2019.0270

Tyson, G. L., and El-Serag, H. B. (2011). Risk factors for cholangiocarcinoma. Hepatology 54 (1), 173–184. doi:10.1002/hep.24351

Ueno, M., Ikeda, M., Morizane, C., Kobayashi, S., Ohno, I., Kondo, S., et al. (2019). Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer. A non-randomised, multicentre, open-label, phase 1 study. Lancet. Gastroenterol. Hepatol. 4 (8), 611–621. doi:10.1016/S2468-1253(19)30086-X

Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anhoney, A., Maraveyas, A., et al. (2010). Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med. 362 (14), 1273–1281. doi:10.1056/NEJMoa0908721

Wang, J., He, Y., Zhang, B., Lv, H., Nie, C., Chen, B., et al. (2022). The efficacy and safety of sintilimab combined with nab-paclitaxel as a second-line treatment for advanced or metastatic gastric cancer and gastroesophageal junction cancer. Front. Oncol. 12, 924149. doi:10.3389/fonc.2022.924149

Winkelmann, R., Schneider, M., Hartmann, S., Schnitzbauer, A. A., Zeuzem, S., Peveling-Oberhag, J., et al. (2018). Microsatellite instability occurs rarely in patients with cholangiocarcinoma: A retrospective study from a German tertiary care hospital. Int. J. Mol. Sci. 19 (5), E1241. doi:10.3390/ijms19051241

Woodford, R., Brungs, D., Leighton, C., Grimison, P., Sjoquist, K. M., Becker, T., et al. (2021). Combination chemotherapy with NAB®-paclitaxel and capecitabine for patients with advanced biliary tract cancer (NAP-CAPABIL Pilot Study). Asia. Pac. J. Clin. Oncol. 18, e220–e226. doi:10.1111/ajco.13599

Xu, F., Jin, T., Zhu, Y., and Dai, C. (2018). Immune checkpoint therapy in liver cancer. J. Exp. Clin. Cancer Res. 37 (1), 110. doi:10.1186/s13046-018-0777-4

Yan, Y., Kumar, A. B., Finnes, H., Markovic, S. N., Park, S., Dronca, R. S., et al. (2018). Combining immune checkpoint inhibitors with conventional cancer therapy. Front. Immunol. 9, 1739. doi:10.3389/fimmu.2018.01739

Zhao, P., Li, L., Jiang, X., and Li, Q. (2019). Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. J. Hematol. Oncol. 12 (1), 54. doi:10.1186/s13045-019-0738-1